Apeiron acquires rights for Phase III immunotherapy against high-risk neuroblastoma from CCRI and SIOPEN

APEIRON Biologics AG (Apeiron) today announced the signing of agreements with the Children’s Cancer Research Institute, Vienna (CCRI) and the European Neuroblastoma Research Network (SIOPEN) that grant Apeiron the rights to further develop and commercialize the monoclonal antibody ch14.18 together with these groups. This antibody presently is being investigated by CCRI and SIOPEN in a Phase III study in high-risk neuroblastoma patients in many centers in Europe. Production is contracted to Polymun Scientific.

The sender takes full responsibility for the content of this news item. Content may include forward-looking statements which, at the time they were made, were based on expectations of future events. Readers are cautioned not to rely on these forward-looking statements.

As a life sciences organization based in Vienna, would you like us to promote your news and events? If so, please send your contributions to news(at)lisavienna.at.